AMGN Stock Recent News
AMGN LATEST HEADLINES
Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Amgen (AMGN) reached $301.29 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolio Brings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., FRCP, FACE as Chief Medical Officer, effective immediately.
In the latest trading session, Amgen (AMGN) closed at $294.76, marking a -1.17% move from the previous day.
This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.